Rallybio Corporation Common Stock

Day range

$16.40 – $16.71

Open

$16.71

Prev close

$16.64

Volume

2.11K

Market cap

$88.4M

Shares out

5.31M

P/E

1.94

P/S

136.84

P/B

0.94

P/FCF

3.31

ROE

48.2%

ROA

46.5%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeSep 9, 2026

  In connection with Mr. Lieber's employment transition, he entered into an agreement ... pursuant to which, following the Employment Transition Date, he will receive a base salary of $420,000 and be entitled to participate in Rallybio's benefit plans, but will not be entitled to receive an annual bonus for 2026 or any subsequent year during which he is employed. Upon his termination, Mr. Lieber will be entitled to severance payments as set forth in his Employment Agreement ... and the Second Amendment to his Employment Agreement.

• Merger agreementJun 1, 2026

  On May 31, 2026, Rallybio Corporation, a Delaware corporation ('Rallybio'), entered into an Agreement and Plan of Merger and Reorganization (the 'Merger Agreement') with Avenzo Therapeutics, Inc., a Delaware corporation ('Avenzo'), a clinical-stage biotechnology company developing next-generation oncology therapies, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio ('Merger Sub'). Upon the terms and subject to the satisfaction of the conditions described in the Merger Agreement, Merger Sub will be merged with and into Avenzo, with Avenzo surviving as a wholly owned subsidiary of Rallybio (the 'Merger' and, together with all of the other transactions contemplated by the Merger Agreement, the 'Contemplated Transactions').

• Deal terminationMay 4, 2026

  On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permitted Alternative Agreement (as defined in the Merger Agreement) with UCB S.A. ('UCB'). As a result of the termination of the Merger Agreement, Rallybio is entitled to receive a $50,000,000 Parent Termination Fee (as defined in the Merger Agreement).

• Executive compensation changeMar 31, 2026

  Dr. Ryder will receive the severance payments and benefits to which he is entitled under his previously disclosed employment agreement with Rallybio upon a termination by Rallybio without cause (the Initial Severance Amounts). In addition, upon the closing of Rallybio's pending business combination with Candid Therapeutics, Inc., Dr. Ryder will receive the severance payments and benefits to which he is entitled under the Employment Agreement upon a termination by Rallybio without cause following a change of control, less the Initial Severance Amounts paid to him.

• Private placementMar 2, 2026

  Concurrently with entering into the Merger Agreement, Candid entered into a subscription agreement (the 'Subscription Agreement') with certain accredited investors (the 'Investors'). Pursuant to the Subscription Agreement, and subject to the terms and conditions therein, Candid agreed to sell, and the Investors agreed to purchase, immediately prior to the Effective Time, shares of Candid common stock for an aggregate purchase price of $505.5 million (the 'Concurrent Financing').

Days to cover

4.9

Short interest

49.25K

Avg volume

10.1K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Halper Sadeh LLC is Investigating Whether QGEN, VCTR, RLYB are Obtaining Fair Deals for their Shareholders
  negativeGlobeNewswire Inc.· Oct 22, 2026
• $HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—ALIS, TALK, JTAI, and RLYB
  negativeGlobeNewswire Inc.· Mar 17, 2026
• Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism
  positiveBenzinga· Mar 2, 2026
• Here's Why Shares in Recursion Pharmaceuticals Surged Today
  positiveThe Motley Fool· Jul 8, 2025
• Why Is Microcap Rallybio Stock Trading Higher On Tuesday?
  positiveBenzinga· Jul 8, 2025